TCTMD -- A high dose of erythropoietin (EPO) delivered soon after successful primary percutaneous coronary intervention (PCI) in patients with a first ST-segment elevation myocardial infarction did not improve ventricular function in the short term, according to recent trial results. However, an apparent reduction in cardiovascular events may warrant testing the treatment in a larger clinical study, the researchers say.
